Regencell Bioscience HoldingsRGC -21.58%33 Interest Coverage is No Debt (1) as of Dec. 2025, which is 100% below its 10-year median of 10,000.00. GuruFocus rates RGC with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 685 Drug Manufacturers companies, Regencell Bioscience Holdings ranks worse than 145985.26% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Regencell Bioscience Holdings's
Operating Income
for the
six
months ended in Dec. 2025 was $-5.34 Mil. Regencell Bioscience Holdings's Interest Expense for the
six
months ended in Dec. 2025 was $0.00 Mil.
Regencell Bioscience Holdings has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Regencell Bioscience Holdings Ltd has enough cash to cover all of its debt. Its financial situation is stable.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Regencell Bioscience Holdings's Interest Coverage or its related term are showing as below:
RGC's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.78 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Regencell Bioscience Holdings Interest Coverage Related Terms
Regencell Bioscience Holdings Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
RGC vs ELAN, NBIX, ALKS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regencell Bioscience Holdings Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Regencell Bioscience Holdings's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Regencell Bioscience Holdings (RGC) has a Interest Coverage of No Debt (1) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Regencell Bioscience Holdings and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, Regencell Bioscience Holdings' Interest Coverage has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, Regencell Bioscience Holdings ranks #999999 out of 685 companies in the Drug Manufacturers industry.
Is Regencell Bioscience Holdings' Interest Coverage too high?
Regencell Bioscience Holdings' current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, Regencell Bioscience Holdings ranks #999999 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regencell Bioscience Holdings has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' Interest Coverage compare to ELAN and NBIX?
According to the Drug Manufacturers industry distribution chart, Regencell Bioscience Holdings ranks #999999 out of 685 companies for Interest Coverage. This places Regencell Bioscience Holdings in the lower half of its industry. The industry median Interest Coverage is 12.78. Historically, Regencell Bioscience Holdings' own Interest Coverage has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Regencell Bioscience Holdings and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regencell Bioscience Holdings's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current Interest Coverage of No Debt (1). The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Regencell Bioscience Holdings' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current Interest Coverage is No Debt (1) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regencell Bioscience Holdings Business Description
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
33GF Score
Get the complete analysis for RGC
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGC has been successfully added to your 
